N/A N=32 Impact of Cyanoacrylate Glue on PICC Line Dressing Care
Central Line Complication · Neonatal Disease
Primary: Duration of Longevity of PICC Line Dressing — 2; 4 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=48 NICU Oxygen Control Study
Hyperoxia · Hypoxia
Primary: Elapsed Time to Respond to SpO2 Alarm — 51.408; 41.523 seconds — p=0.003
N/A N=120 Effects of Personalized Actionable Connected Extensible (PACE) Interventions Among Patients With Chronic Kidney Disease
CKD - Chronic Kidney Disease
Primary: Tilburg Frailty Indicator (TFI) — 5.38; 4.97; 4.16; 4.16 score on a scale
N/A N=11 Clinical Investigation Exploring Two Ostomy Product Prototypes
Stoma Ileostomy
Primary: Primary Objective — 7; 4; 1; 4 Participants
N/A N=505 CBT Texts for PTSD & Hazardous Drinking (Project Better)
Posttraumatic Stress Disorder · Alcohol Use
Primary: Heavy Episodic Drinking — 6.19; 6.00; 5.85; 6.69 number of heavy drinking episodes
Phase 2 N=37 Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
Acute Myeloid Leukemia · Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 16; 31; 39; 46 Participants
N/A N=27 Care of Persons With Dementia in Their Environments (COPE) in Programs of All-Inclusive Care of the Elderly (PACE)
Frontotemporal Dementia · Dementia · Multi-Infarct Dementia
Primary: Determinants of Implementation Behavior Questionnaire (Clinicians) — 0.06; -0.25; 0.33; 0.06 score on a scale
Phase 1 N=61 Combination HTNV and PUUV DNA Vaccine
Hantaan Virus Disease, Puumala Virus
Primary: Summary of Solicited Local Adverse Events (AEs) — 8; 11; 12; 9 Participants
N/A N=33 SMART Stimulation: Precision Neuromodulation of Cognition in Older Adults
Aging
Primary: N-Back Working Memory — .2030; .0731 percent change
N/A N=163 Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings
Opioid-Related Disorders
Primary: Pain Interference Based on the Brief Pain Inventory — 5.01; 4.67 units on a scale
Phase 3 N=147 Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
COVID-19
Primary: Neutralizing Antibody (Nab) for SARS-CoV-2 Wildtype Virus (Wuhan) Responses Expressed as Geometric Mean Titers (GMT) — 173.2; 159.5; 396.6; 436.0 titers
N/A N=105 A Study on the Use of Real -Time Continuous Glucose Monitoring (RT-CGM) in Gestational Diabetes
Gestational Diabetes
Primary: Mean Glucose — 103.0; 106.2 mg/dl
Phase 1 N=81 Remote Mindfulness Training Following Early Life Adversity
Stress · Mindfulness · Early Life Adversity
Primary: Feasibility of Recruitment (Screened Eligible) — 81; 56; 112; 642 Participants
N/A N=21 A Prenatal Bonding Intervention for Pregnant Women With Depression
Depression · Pregnancy
Primary: Change on Maternal Antenatal Attachment Scale (MAAS) — 69.7; 72.4; 75.9 score on a scale
Phase 2 N=319 Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain
Diabetic Peripheral Neuropathy · Diabetes
Primary: Change From Baseline to Week 6 in ADPS as Measured by the Numerical Rating Scale — -0.72; -1.39; -1.27 score on a scale — p=0.007